Treatment of small cell lung cancer in academic and community settings: Factors associated with receiving standard therapy and survival

Cancer Journal (United States)

Volumn 20, Issue 2, 2014, Pages 97-104

  Parsons, Helen M ^a   Harlan, Linda C ^a   Stevens, Jennifer L ^b   Ullmann, Claudio Dansky ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INFORMATION MANAGEMENT SERVICES INC   (United States)

Author keywords

lung cancer; small cell; survival; treatment patterns

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; ETOPOSIDE; IRINOTECAN;

ADULT; AGED; ARTICLE; ATELECTASIS; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); COMMUNITY HOSPITAL; CONTROLLED STUDY; FEMALE; HEALTH HAZARD; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH ORGANIZATION; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RESIDENTIAL CARE; TREATMENT PLANNING; TREATMENT REFUSAL; UNITED STATES; UNIVERSITY HOSPITAL; HEALTH CARE QUALITY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SMALL CELL LUNG CARCINOMA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; ETOPOSIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; SMALL CELL LUNG CARCINOMA; STANDARD OF CARE;

EID: 84897555023     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000039     Document Type: Article

References (31)

1. American Cancer Society. Cancer Facts and Figures. American Cancer Society. Available at: http://www.cancer.org/acs/groups/content/ @epidemiologysurveilance/documents/document/acspc-036845.pdf. Accessed December 3, 2013. 2013.
2. De Vita VTJ, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. Small cell lung cancer, 7th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2005.
3. General Information about Small Cell Lung Cancer. (2013). Available at: http://www.cancer.gov/cancertopics/pdq/treatment/small-cell-lung/ healthprofessional/page1. Accessed December 3, 2013.
4. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24:4539-4544.
5. NCCN clinical practice guidelines in oncology (NCCN GuidelinesTM): small cell lung cancer. (2012). Available at: http://www.nccn.org/ professionals/physician-gls/pdf/sclc.pdf. Accessed December 3, 2013.
6. Slotman B, Faivre-Finn C, Kramer G, et al., Group ERO, Lung Cancer G. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357:664-672.
7. Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341:476-484.
8. Agra Y, Pelayo M, Sacristan M, et al. Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database Syst Rev. 2003;CD001990.
9. Turrisi AT3rd, Kim K, Blum R, et al. Twice-daily compared with oncedaily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340:265-271.
10. Klasa RJ, Murray N, Coldman AJ Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol. 1991;9:499-508.
11. Amarasena IU, Walters JA, Wood-Baker R, et al. Platinum versus nonplatinum chemotherapy regimens for small cell lung cancer. Cochrane Database Syst Rev. 2008;CD006849.
12. Arriagada R, Le Chevalier T, Pignon JP, et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med. 1993;329:1848-1852.
13. Elias AD, Ayash L, Frei E3rd, et al. Intensive combined modality therapy for limited-stage small-cell lung cancer. J Natl Cancer Inst. 1993;85:559-566.
14. Ihde DC, Mulshine JL, Kramer BS, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol. 1994;12:2022-2034.
15. Murray N, Livingston RB, Shepherd FA, et al. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol. 1999;17:2300-2308.
16. Stinchcombe TE, Bogart J, Wigle DA, et al. Annual review of advances in lung cancer clinical research: a report for the year 2009. J Thorac Oncol. 2010;5:935-939.
17. Fry WA, Phillips JL, Menck HR Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer. 1999;86:1867-1876.
18. Surveillance, Epidemiology and End Results (SEER) ProgramResearchData (1973-2010). (2013). Available at: http://www.seer.cancer.gov. 2013.
19. Surveillance Epidemiology and End Results Patterns of Care Studies (2013). Available at: http://seer.cancer.gov/studies/endresults/study23. html. Accessed December 3, 2013.
20. Shepherd FA Surgery for limited stage small cell lung cancer: time to fish or cut bait. J Thorac Oncol. 2010;5:147-149.
21. Shepherd FA. Surgical management of small cell lung cancer. In: Franco KL, Putnam JB (eds) Advanced Therapy in Thoracic Surgery. 2nd ed. Decker, Hamilton, BC; 2005:101-112.
22. Lara PNJr, Natale R, Crowley J, et al. Phase III trial of irinotecan/ cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009;27:2530-2535.
23. Hartz AJ, Krakauer H, Kuhn EM, et al. Hospital characteristics and mortality rates. N Engl J Med. 1989;321:1720-1725.
24. Sloan FA, Trogdon JG, Curtis LH, et al. Does the ownership of the admitting hospital make a difference? Outcomes and process of care of Medicare beneficiaries admitted with acute myocardial infarction. Medical Care. 2003;41:1193-1205.
25. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
26. Ludbrook JJ, Truong PT, MacNeil MV, et al. Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? A community-based population analysis. Int J Radiat Oncol Biol Phys. 2003;55:1321-1330.
27. Davis S,Wright PW, Schulman SF, et al. Long-termsurvival in small-cell carcinoma of the lung: a population experience. J Clin Oncol. 1985;3:80-91.
28. Lally BE, GeigerAM, Urbanic JJ, et al. Trends in the outcomes for patients with limited stage small cell lung cancer: an analysis of the Surveillance, Epidemiology, and End Results database. Lung Cancer. 2009;64:226-231.
29. Hermes A, Waschki B, Gatzemeier U, et al. Characteristics, treatment patterns and outcomes of patients with small cell lung cancer - a retrospective single institution analysis. Lung Cancer. 2011;71:363-366.
30. Miller BA, Chu KC, Hankey BF, et al. Cancer incidence and mortality patterns among specific Asian and Pacific Islander populations in the U.S. Cancer Causes Control. 2008;19:227-256.
31. Dinan MA, Curtis LH, Hammill BG, et al. Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999-2006. JAMA. 2010;303:1625-1631.